Abstract
Objective
To evaluate whether the calcium-channel blocker diltiazem has protective effects against cisplatin-induced ototoxicity in a mouse model.
Study Design
Original basic science in vivo investigation.
Setting
Academic setting: Otolaryngology–Head and Neck Surgery laboratory at University of Connecticut Health Center.
Subjects
Thirty-nine female CBA/J mice.
Methods
Pure tone– or click-evoked auditory brainstem responses (ABRs) were recorded in CBA/J mice to determine auditory thresholds. All mice had baseline ABRs recorded. They were then given a single cisplatin bolus (14 mg/kg), followed by 5 consecutive days of intratympanic diltiazem or saline control. Follow-up thresholds were recorded on days 7, 14, and 21 postcisplatin. Tone-evoked ABRs evaluated the otoprotective effect of 2-mg/kg diltiazem in 9 mice, and dose effect was examined in response to click-evoked ABR with 2- or 4-mg/kg diltiazem in 2 groups of 15 mice.
Results
Saline-treated ears had significantly elevated tone-evoked auditory thresholds when compared with diltiazem-treated ears (
Conclusion
Intratympanic diltiazem has significant protective effects against cisplatin ototoxicity at 2 and 4 mg/kg. This is the first in vivo study to demonstrate that diltiazem offers a potentially novel therapy for cisplatin-induced ototoxicity.
Get full access to this article
View all access options for this article.
